October 21, 2014 10:23 AM ET

Biotechnology

Company Overview of DermTech International

Company Overview

DermTech International, a molecular diagnostic company, is engaged in developing and marketing gene expression tests to facilitate the diagnosis of dermatologic conditions. The company offers Adhesive Skin Sample Collection Kit, which consists of adhesive patches, instructions for use, a marking pen for lesion outlining, and a pre-addressed and prepaid return shipping pack. Its Adhesive Skin Sample Collection Kit allows for the collection of skin samples with minimal patient discomfort. The company also provides Pigmented Lesion Assay for reducing unnecessary surgical biopsy procedures and enhancing diagnostic accuracy; ribonucleic acid extraction services; and a smart phone based photoinfor...

11099 North Torrey Pines Road

Suite 100

La Jolla, CA 92037

United States

Founded in 1995

20 Employees

Phone:

858-450-4222

Fax:

858-200-3877

Key Executives for DermTech International

Chief Executive Officer
Age: 48
Chief Financial Officer
Age: 58
Chief Operating Officer
Age: 50
Chief Medical Officer
Director of Business Administration
Compensation as of Fiscal Year 2014.

DermTech International Key Developments

DermTech International Adds Three Members to its Commercialization Team

DermTech International announced that it has added three members to its commercialization team. Art Wampole will lead the company's sales effort, Annie Bell will lead the company's marketing strategy, and Mildred Romero will lead the company's reimbursement implementation. Art Wampole was previously the Vice President of Sales at Dermpath Diagnostics. Annie Bell held senior management positions in Sales and Marketing for Ameripath Inc. and was the general manager of Dermpath Diagnostics. Mildred Romero has held senior management positions and led reimbursement development at several innovative diagnostics companies including DexCom Inc. and Pathway Genomics Corporation.

DermTech International Auditor Raises 'Going Concern' Doubt

DermTech International filed its Annual on May 09, 2014 for the period ending Dec 31, 2013. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

DermTech Seeks Acquisitions

DermTech International to seek acquisitions. DermTech International has filed for an initial public offering for $25 million, the proceeds of which will be used to acquire, invest in, or license complementary products, technologies, or businesses although we have no current commitments, understandings, or agreements to do so.

Similar Private Companies By Industry

Company Name Region
New KCBX, Inc. United States
Ravgen, Inc. United States
Earth BioSciences Inc. United States
MitoPharm Corporation United States
Evogene, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DermTech International, please visit www.dermtech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.